Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Romidepsin (ISTODAX®) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

NCT01590732 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT01590732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01590732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Romidepsin (ISTODAX®) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
October 29, 2012
Completion date
May 2, 2018
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mycosis fungoides, recurrent anaplastic large cell lymphoma, recurrent angioimmunoblastic t-cell lymphoma, recurrent enteropathy-associated t-cell lymphoma, recurrent hepatosplenic t-cell lymphoma, recurrent peripheral t-cell lymphoma, not otherwise specified, refractory anaplastic large cell lymphoma, refractory angioimmunoblastic t-cell lymphoma, refractory enteropathy-associated t-cell lymphoma, refractory hepatosplenic t-cell lymphoma, refractory peripheral t-cell lymphoma, not otherwise specified